OrthO-rheumatO | VOL 11 | Nr 5 | 2013
13
resultaat, aangemoedigd. De integratie in de dagelijkse
praktijk van specifiekere testen, zoals de domein-I-
2
GPI-
antilichamen, is afhankelijk van verder onderzoek in grote
klinische studies en van de commerciële beschikbaarheid.
Het optimaliseren van de huidige testen en het zoeken
naar nieuwe testen gaat verder om patiënten met AFA en
verhoogd risico op trombose te kunnen identificeren. De
laboratoriumresultaten moeten steeds geïnterpreteerd
worden in functie van het klinische vermoeden van AFS.
Om die reden is een goede samenwerking en wederzijdse
uitwisseling van informatie tussen clinicus en laborato-
rium noodzakelijk.
referenties
1. miyakis s, lockshin md, atsumi T, et al. international consensus statement on an update
of the classification criteria for definite antiphospholipid syndrome (aPs). j Thromb
haemost 2006;4(2):295-306.
2. de moerloose P, reber g, musial j, arnout j. analytical and clinical performance of a
new, automated assay panel for the diagnosis of antiphospholipid syndrome. j Thromb
haemost 2010;8(7):1540-6.
3. Persijn l, decavele as, schouwers s, devreese k. evaluation of a new set of automated
chemiluminescense assays for anticardiolipin and anti-beta2-glycoprotein i
antibodies in the laboratory diagnosis of the antiphospholipid syndrome. Thromb res
2011;128(6):565-9.
4. Van hoecke f, Persijn l, decavele as, devreese k. Performance of two new, automated
chemiluminescense assay panels for anticardiolipin and anti-beta2-glycoprotein i
antibodies in the laboratory diagnosis of the antiphospholipid syndrome. int j lab
hematol 2012; in press.
5. galli m, Comfurius P, maassen C, et al. anticardiolipin antibodies (aCa) directed not to
cardiolipin but to a plasma protein cofactor. lancet 1990;335(8705):1544-7.
6. de groot Pg, urbanus rT. The significance of autoantibodies against beta2-glycoprotein
i. blood 2012;120(2):266-74.
7. wilson wa, gharavi ae, koike T, et al. international consensus statement on preliminary
classification criteria for definite antiphospholipid syndrome: report of an international
workshop. arthritis rheum 1999;42(7):1309-11.
8. devreese k, hoylaerts mf. laboratory diagnosis of the antiphospholipid syndrome: a
plethora of obstacles to overcome. eur j haematol 2009;83(1):1-16.
9. giannakopoulos b, krilis sa. how i treat the antiphospholipid syndrome. blood
2009;114(10):2020-30.
10. devreese k. standardization of antiphospholipid antibody assays. where do we stand?
lupus 2012;21(7):718-21.
11. devreese k, hoylaerts mf. Challenges in the diagnosis of the antiphospholipid syndrome.
Clin Chem 2010;56(6):930-40.
12. urbanus rT, de groot Pg. antiphospholipid antibodies--we are not quite there yet. blood
rev 2011;25(2):97-106.
13. Pengo V, Tripodi a, reber g, et al. update of the guidelines for lupus anticoagulant
detection. subcommittee on lupus anticoagulant/antiphospholipid antibody of the
scientific and standardisation Committee of the international society on Thrombosis and
haemostasis. j Thromb haemost 2009;7(10):1737-40.
14. de groot Pg, meijers jC, urbanus rT. recent developments in our understanding of the
antiphospholipid syndrome. int j lab hematol 2012;34(3):223-31.
15. de laat hb, derksen rh, urbanus rT, roest m, de groot Pg. beta2-glycoprotein
i-dependent lupus anticoagulant highly correlates with thrombosis in the
antiphospholipid syndrome. blood 2004;104(12):3598-602.
16. Cervera r, khamashta ma, shoenfeld y, et al. morbidity and mortality in the
antiphospholipid syndrome during a 5-year period: a multicentre prospective study of
1000 patients. ann rheum dis 2009;68(9):1428-32.
17. devreese km. antiphospholipid antibodies: evaluation of the thrombotic risk. Thromb
res 2012;130(suppl 1):s37-40.
18. hughes gr, mackworth-young C, harris en, gharavi ae. Veno-occlusive disease in
systemic lupus erythematosus: possible association with anticardiolipin antibodies?
arthritis rheum 1984;27(9):1071.
19. galli m, luciani d, bertolini g, barbui T. lupus anticoagulants are stronger risk factors
for thrombosis than anticardiolipin antibodies in the antiphospholipid syndrome: a
systematic review of the literature. blood 2003;101(5):1827-32.
20. urbanus rT, siegerink b, roest m, et al. antiphospholipid antibodies and risk of
myocardial infarction and ischaemic stroke in young women in the raTio study: a case-
control study. lancet neurol 2009;8(11):998-1005.
21. brey rl, abbott rd, Curb jd, et al. beta(2)-glycoprotein 1-dependent anticardiolipin
antibodies and risk of ischemic stroke and myocardial infarction: the honolulu heart
program. stroke 2001;32(8):1701-6.
22. de groot Pg, lutters b, derksen rh, et al. lupus anticoagulants and the risk of a first
episode of deep venous thrombosis. j Thromb haemost 2005;3(9):1993-7.
23. galli m, reber g, de moerloose P, de groot Pg. invitation to a debate on the serological
criteria that define the antiphospholipid syndrome. j Thromb haemost 2008;6(2):399-
401.
24. de laat b, derksen rh, urbanus rT, de groot Pg. igg antibodies that recognize epitope
gly40-arg43 in domain i of beta 2-glycoprotein i cause laC, and their presence correlates
strongly with thrombosis. blood 2005;105(4):1540-5.
25. de laat b, Pengo V, Pabinger i, et al. The association between circulating antibodies
against domain i of beta2-glycoprotein i and thrombosis: an international multicenter
study. j Thromb haemost 2009;7(11):1767-73.
26. devreese k, Peerlinck k, hoylaerts mf. diagnostic test combinations associated with
thrombosis in lupus anticoagulant positive patients. Thromb haemost 2011;105(4):736-
8.
27. Pengo V, ruffatti a, legnani C, et al. Clinical course of high-risk patients diagnosed with
antiphospholipid syndrome. j Thromb haemost 2010;8(2):237-42.
28. danowski a, kickler Ts, Petri m. anti-beta2-glycoprotein i: prevalence, clinical
correlations, and importance of persistent positivity in patients with antiphospholipid
syndrome and systemic lupus erythematosus. j rheumatol 2006;33(9):1775-9.
29. kumar s, Papalardo e, sunkureddi P, najam s, gonzalez eb, Pierangeli ss. isolated
elevation of iga anti-beta2glycoprotein i antibodies with manifestations of
antiphospholipid syndrome: a case series of five patients. lupus 2009;18(11):1011-4.
30. devreese km. a functional coagulation test to identify anti-beta2-glycoprotein i
dependent lupus anticoagulants. Thromb res 2007;119(6):753-9.
31. de laat b, derksen rh, reber g, et al. an international multicentre-laboratory evaluation
of a new assay to detect specifically lupus anticoagulants dependent on the presence of
anti-beta2-glycoprotein autoantibodies. j Thromb haemost 2011;9(1):149-53.
32. devreese k, Peerlinck k, arnout j, hoylaerts mf. laboratory detection of the
antiphospholipid syndrome via calibrated automated thrombography. Thromb haemost
2009;101(1):185-96.
33. devreese k, Peerlinck k, hoylaerts mf. Thrombotic risk assessment in the
antiphospholipid syndrome requires more than the quantification of lupus
anticoagulants. blood 2010;115(4):870-8.
34. Tripodi a, Chantarangkul V, Clerici m, et al. standardization of lupus anticoagulant.
feasibility study of a calibration model to minimize between-method variability. Thromb
res 2011;127(6):589-94.
35. Pengo V. antiphospholipid syndrome: interpretation of laboratory data. j Thromb
haemost 2011;9(2):402-3.
36. Pelkmans l, de laat b. antibodies against domain i of beta2-glycoprotein i: the one and
only? lupus 2012;21(7):769-72.
37. Pengo V, denas g, banzato a, et al. interpretation of laboratory data and need for
reference laboratories. lupus 2012;21(7):732-3.
38. Pengo V, ruffatti a, legnani C, et al. incidence of a first thromboembolic event in
asymptomatic carriers of high-risk antiphospholipid antibody profile: a multicenter
prospective study. blood 2011;118(17):4714-8.